This finding is in contrast with previous studies which reported that activated AKT signaling compromised the therapeutic effects of the chemotherapeutic agents used in the treatment of GBM (Hirose et al., 2005; Yin et al., 2014). This evidence concerns the gene AKT1 and glioblastoma.